학술논문
Both COVID-19 infection and vaccination induce high-affinity cross-clade responses to SARS-CoV-2 variants.
Document Type
Academic Journal
Author
Emmenegger M; Institute of Neuropathology, University of Zurich, 8091 Zurich, Switzerland.; Fiedler S; Fluidic Analytics, Unit A, The Paddocks Business Centre, Cherry Hinton Road, Cambridge CB1 8DH, UK.; Brugger SD; Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.; Devenish SRA; Fluidic Analytics, Unit A, The Paddocks Business Centre, Cherry Hinton Road, Cambridge CB1 8DH, UK.; Morgunov AS; Fluidic Analytics, Unit A, The Paddocks Business Centre, Cherry Hinton Road, Cambridge CB1 8DH, UK.; Centre for Misfolding Diseases, Yusuf Hamied Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK.; Ilsley A; Fluidic Analytics, Unit A, The Paddocks Business Centre, Cherry Hinton Road, Cambridge CB1 8DH, UK.; Ricci F; Fluidic Analytics, Unit A, The Paddocks Business Centre, Cherry Hinton Road, Cambridge CB1 8DH, UK.; Malik AY; Fluidic Analytics, Unit A, The Paddocks Business Centre, Cherry Hinton Road, Cambridge CB1 8DH, UK.; Scheier T; Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.; Batkitar L; Institute of Neuropathology, University of Zurich, 8091 Zurich, Switzerland.; Madrigal L; Institute of Neuropathology, University of Zurich, 8091 Zurich, Switzerland.; Rossi M; Department of Laboratory Medicine, University Hospital Zürich, 8091 Zurich, Switzerland.; Meisl G; Centre for Misfolding Diseases, Yusuf Hamied Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK.; Lynn AK; Fluidic Analytics, Unit A, The Paddocks Business Centre, Cherry Hinton Road, Cambridge CB1 8DH, UK.; Saleh L; Department of Laboratory Medicine, University Hospital Zürich, 8091 Zurich, Switzerland.; von Eckardstein A; Department of Laboratory Medicine, University Hospital Zürich, 8091 Zurich, Switzerland.; Knowles TPJ; Fluidic Analytics, Unit A, The Paddocks Business Centre, Cherry Hinton Road, Cambridge CB1 8DH, UK.; Centre for Misfolding Diseases, Yusuf Hamied Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK.; Cavendish Laboratory, Department of Physics, University of Cambridge, JJ Thomson Ave, Cambridge CB3 0HE, UK.; Aguzzi A; Institute of Neuropathology, University of Zurich, 8091 Zurich, Switzerland.
Source
Publisher: Cell Press Country of Publication: United States NLM ID: 101724038 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2589-0042 (Electronic) Linking ISSN: 25890042 NLM ISO Abbreviation: iScience Subsets: PubMed not MEDLINE
Subject
Language
English
Abstract
The B.1.1.529 (omicron) variant has rapidly supplanted most other SARS-CoV-2 variants. Using microfluidics-based antibody affinity profiling (MAAP), we have characterized affinity and IgG concentration in the plasma of 39 individuals with multiple trajectories of SARS-CoV-2 infection and/or vaccination. Antibody affinity was similar against the wild-type, delta, and omicron variants ( K A ranges: 122 ± 155, 159 ± 148, 211 ± 307 μM -1 , respectively), indicating a surprisingly broad and mature cross-clade immune response. Postinfectious and vaccinated subjects showed different IgG profiles, with IgG3 (p-value = 0.002) against spike being more prominent in the former group. Lastly, we found that the ELISA titers correlated linearly with measured concentrations (R = 0.72) but not with affinity (R = 0.29). These findings suggest that the wild-type and delta spike induce a polyclonal immune response capable of binding the omicron spike with similar affinity. Changes in titers were primarily driven by antibody concentration, suggesting that B-cell expansion, rather than affinity maturation, dominated the response after infection or vaccination.
Competing Interests: TPJK is a member of the board of directors of Fluidic Analytics. AA is a member of the clinical and scientific advisory board of Fluidic Analytics. AA is a member of the board of directors of Mabylon AG and AB2Bio AG. AKL, SF, SRAD, ASM, AYM, AI, and FR are employees of Fluidic Analytics. GM is a technical consultant for Fluidic Analytics. All other authors declare no competing interest.
(© 2022 The Author(s).)
Competing Interests: TPJK is a member of the board of directors of Fluidic Analytics. AA is a member of the clinical and scientific advisory board of Fluidic Analytics. AA is a member of the board of directors of Mabylon AG and AB2Bio AG. AKL, SF, SRAD, ASM, AYM, AI, and FR are employees of Fluidic Analytics. GM is a technical consultant for Fluidic Analytics. All other authors declare no competing interest.
(© 2022 The Author(s).)